These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29184171)

  • 1. Points to consider for laboratories reporting results from diagnostic genomic sequencing.
    Vears DF; Sénécal K; Clarke AJ; Jackson L; Laberge AM; Lovrecic L; Piton A; Van Gassen KLI; Yntema HG; Knoppers BM; Borry P
    Eur J Hum Genet; 2018 Jan; 26(1):36-43. PubMed ID: 29184171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reporting practices for variants of uncertain significance from next generation sequencing technologies.
    Vears DF; Sénécal K; Borry P
    Eur J Med Genet; 2017 Oct; 60(10):553-558. PubMed ID: 28774848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reporting practices for unsolicited and secondary findings from next-generation sequencing technologies: Perspectives of laboratory personnel.
    Vears DF; Sénécal K; Borry P
    Hum Mutat; 2017 Aug; 38(8):905-911. PubMed ID: 28512758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories.
    O'Daniel JM; McLaughlin HM; Amendola LM; Bale SJ; Berg JS; Bick D; Bowling KM; Chao EC; Chung WK; Conlin LK; Cooper GM; Das S; Deignan JL; Dorschner MO; Evans JP; Ghazani AA; Goddard KA; Gornick M; Farwell Hagman KD; Hambuch T; Hegde M; Hindorff LA; Holm IA; Jarvik GP; Knight Johnson A; Mighion L; Morra M; Plon SE; Punj S; Richards CS; Santani A; Shirts BH; Spinner NB; Tang S; Weck KE; Wolf SM; Yang Y; Rehm HL
    Genet Med; 2017 May; 19(5):575-582. PubMed ID: 27811861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of VUS reporting, variant reinterpretation and recontact policies in clinical genomic sequencing consent forms.
    Vears DF; Niemiec E; Howard HC; Borry P
    Eur J Hum Genet; 2018 Dec; 26(12):1743-1751. PubMed ID: 30143804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of laboratory reporting practices using a quality assessment of a virtual patient.
    Vears DF; Elferink M; Kriek M; Borry P; van Gassen KL
    Genet Med; 2021 Mar; 23(3):562-570. PubMed ID: 33122805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.
    Amendola LM; Jarvik GP; Leo MC; McLaughlin HM; Akkari Y; Amaral MD; Berg JS; Biswas S; Bowling KM; Conlin LK; Cooper GM; Dorschner MO; Dulik MC; Ghazani AA; Ghosh R; Green RC; Hart R; Horton C; Johnston JJ; Lebo MS; Milosavljevic A; Ou J; Pak CM; Patel RY; Punj S; Richards CS; Salama J; Strande NT; Yang Y; Plon SE; Biesecker LG; Rehm HL
    Am J Hum Genet; 2016 Jun; 98(6):1067-1076. PubMed ID: 27181684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should we respect parents' views about which results to return from genomic sequencing?
    Vears DF
    Hum Genet; 2022 May; 141(5):1059-1068. PubMed ID: 33987713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
    Eccles DM; Mitchell G; Monteiro AN; Schmutzler R; Couch FJ; Spurdle AB; Gómez-García EB;
    Ann Oncol; 2015 Oct; 26(10):2057-65. PubMed ID: 26153499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do consent forms for diagnostic high-throughput sequencing address unsolicited and secondary findings? A content analysis.
    Vears DF; Niemiec E; Howard HC; Borry P
    Clin Genet; 2018 Oct; 94(3-4):321-329. PubMed ID: 29888485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding variations in secondary findings reporting practices across U.S. genome sequencing laboratories.
    Ackerman SL; Koenig BA
    AJOB Empir Bioeth; 2018; 9(1):48-57. PubMed ID: 29131714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Old Challenges or New Issues? Genetic Health Professionals' Experiences Obtaining Informed Consent in Diagnostic Genomic Sequencing.
    Vears DF; Borry P; Savulescu J; Koplin JJ
    AJOB Empir Bioeth; 2021; 12(1):12-23. PubMed ID: 33017265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing.
    Balmaña J; Digiovanni L; Gaddam P; Walsh MF; Joseph V; Stadler ZK; Nathanson KL; Garber JE; Couch FJ; Offit K; Robson ME; Domchek SM
    J Clin Oncol; 2016 Dec; 34(34):4071-4078. PubMed ID: 27621404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of a multidisciplinary team in managing variants of uncertain clinical significance in prenatal genetic diagnosis.
    Diderich KEM; Klapwijk JE; van der Schoot V; van den Born M; Wilke M; Joosten M; Stuurman KE; Hoefsloot LH; Van Opstal D; Brüggenwirth HT; Srebniak MI
    Eur J Med Genet; 2023 Oct; 66(10):104844. PubMed ID: 37709011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCMG practice guideline: laboratory guidelines for next-generation sequencing.
    Hume S; Nelson TN; Speevak M; McCready E; Agatep R; Feilotter H; Parboosingh J; Stavropoulos DJ; Taylor S; Stockley TL;
    J Med Genet; 2019 Dec; 56(12):792-800. PubMed ID: 31300550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variant Classification Concordance using the ACMG-AMP Variant Interpretation Guidelines across Nine Genomic Implementation Research Studies.
    Amendola LM; Muenzen K; Biesecker LG; Bowling KM; Cooper GM; Dorschner MO; Driscoll C; Foreman AKM; Golden-Grant K; Greally JM; Hindorff L; Kanavy D; Jobanputra V; Johnston JJ; Kenny EE; McNulty S; Murali P; Ou J; Powell BC; Rehm HL; Rolf B; Roman TS; Van Ziffle J; Guha S; Abhyankar A; Crosslin D; Venner E; Yuan B; Zouk H; ; Jarvik GP
    Am J Hum Genet; 2020 Nov; 107(5):932-941. PubMed ID: 33108757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Offering preimplantation genetic testing for monogenic disorders (PGT-M) for conditions with reduced penetrance or variants of uncertain significance: Ethical insight from U.S. laboratory genetic counselors.
    Porto A; Gaber Caffrey R; Crowley-Matoka M; Spencer S; Li M; Propst L
    J Genet Couns; 2022 Feb; 31(1):261-268. PubMed ID: 34347921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of variation in practice in the prenatal reporting of variants of uncertain significance by commercial laboratories: Need for greater adherence to published guidelines.
    Cornthwaite M; Turner K; Armstrong L; Boerkoel CF; Chang C; Lehman A; Nikkel SM; Patel MS; Van Allen M; Langlois S
    Prenat Diagn; 2022 Nov; 42(12):1514-1524. PubMed ID: 36068917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic health professionals' experiences with initiating reanalysis of genomic sequence data.
    Vears DF; Sénécal K; Borry P
    Fam Cancer; 2020 Jul; 19(3):273-280. PubMed ID: 32200539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.